X S Zhang, B C Liu, X Du, Y L Zhang, N Xu, X L Liu, W M Li, H Lin, R Liang, C Y Chen, J Huang, Y F Yang, H L Zhu, L Pan, X D Wang, G H Li, Z G Liu, Y Q Zhang, Z F Liu, J D Hu, C S Liu, F Li, W Yang, L Meng, Y Q Han, L E Lin, Z Y Zhao, C Q Tu, C F Zheng, Y L Bai, Z P Zhou, S N Chen, H Y Qiu, L J Yang, X L Sun, H Sun, L Zhou, Z L Liu, D Y Wang, J X Guo, L P Pang, Q S Zeng, X H Suo, W H Zhang, Y J Zheng, Q Jiang
Objective: To retrospectively analyze the treatment status of tyrosine kinase inhibitors (TKI) in newly diagnosed patients with chronic myeloid leukemia (CML) in China. Methods: Data of chronic phase (CP) and accelerated phase (AP) CML patients diagnosed from January 2006 to December 2022 from 77 centers, ≥18 years old, and receiving initial imatinib, nilotinib, dasatinib or flumatinib-therapy within 6 months after diagnosis in China with complete data were retrospectively interrogated. The choice of initial TKI, current TKI medications, treatment switch and reasons, treatment responses and outcomes as well as the variables associated with them were analyzed...
March 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi